A trial of intra-pleural bacterial immunotherapy in malignant pleural mesothelioma (TILT) — a randomised feasibility study using the trial within a cohort (TwiC) methodology

MLA

Anna C. Bibby, et al. “A Trial of Intra-Pleural Bacterial Immunotherapy in Malignant Pleural Mesothelioma (TILT) — a Randomised Feasibility Study Using the Trial within a Cohort (TwiC) Methodology.” Pilot and Feasibility Studies, vol. 8, no. 1, Sept. 2022, pp. 1–12. EBSCOhost, https://doi.org/10.1186/s40814-022-01156-3.

APA

Anna C. Bibby, Natalie Zahan-Evans, Emma Keenan, Charles Comins, John E. Harvey, Helen Day, Najib M. Rahman, Janet E. Fallon, Rachael Gooberman-Hill, & Nick A. Maskell. (2022). A trial of intra-pleural bacterial immunotherapy in malignant pleural mesothelioma (TILT) — a randomised feasibility study using the trial within a cohort (TwiC) methodology. Pilot and Feasibility Studies, 8(1), 1–12. https://doi.org/10.1186/s40814-022-01156-3

Chicago

Anna C. Bibby, Natalie Zahan-Evans, Emma Keenan, Charles Comins, John E. Harvey, Helen Day, Najib M. Rahman, Janet E. Fallon, Rachael Gooberman-Hill, and Nick A. Maskell. 2022. “A Trial of Intra-Pleural Bacterial Immunotherapy in Malignant Pleural Mesothelioma (TILT) — a Randomised Feasibility Study Using the Trial within a Cohort (TwiC) Methodology.” Pilot and Feasibility Studies 8 (1): 1–12. doi:10.1186/s40814-022-01156-3.